Recombinant Human IL6 Protein, non-tagged, Biotinylated

• Cat.No.: IL6-040H
• Product Overview: Biotinylated Human IL-6 is expressed from HEK293 cells. It contains AA Val 30 - Met 212 (Accession # NP_000591). The product does not contain any epitope tags.

Specification

• Source: HEK293
• Species: Human
• Predicted N Terminal: Val 30
• Form: Lyophilized from 0.22 um filtered solution in PBS, pH7.4, 10% trehalose.
• Molecular Mass: The protein has a calculated MW of 20.8 kDa. The protein migrates as 24-27 kDa on a SDS-PAGE gel under reducing condition due to different glycosylation.
• Endotoxin: < 1.0 EU per μg of the protein as determined by the LAL method.
• Purity: >95% as determined by SDS-PAGE.
• Characteristic: The primary amines in the side chains of lysine residues and the N-terminus of the protein are conjugated with biotins using standard chemical labeling method. A standard biotin reagent (13.5 angstroms) is used in this product. The biotin to protein ratio is 4-5.5 as determined by the HABA assay.
• Stability: Samples are stable for up to twelve months from date of receipt at -70ºC.
• Storage: For long term storage, the product should be stored at lyophilized state at -20ºC or lower. Please avoid repeated freeze-thaw cycles. No activity loss is observed after storage at: 4-8ºC for 12 months in lyophilized state; -70ºC for 3 months under sterile conditions after reconstitution.
• Reconstitution: It is recommended that sterile water be added to the vial to prepare a stock solution of 0.2 ug/ul. Centrifuge the vial at 4℃ before opening to recover the entire contents.
• Tag: Non
• Protein length: Val30-Met212

Gene Information

• Gene Name: IL6 interleukin 6 (interferon, beta 2) [ Homo sapiens ]
• Official Symbol: IL6
• Synonyms: IL6; interleukin 6 (interferon, beta 2); IFNB2; interleukin-6; BSF2; HGF; HSF; IL 6; CDF; BSF-2; IFN-beta-2; interferon beta-2; interleukin BSF-2; hybridoma growth factor; CTL differentiation factor; B-cell stimulatory factor 2; B-cell differentiation factor; IL-6
• Gene ID: 3569
• mRNA Refseq: NM_000600
• Protein Refseq: NP_000591
• MIM: 147620
• UniProt ID: P05231

Reviews

03/05/2022

Accurate localization and function within the cell.

01/31/2021

The binding affinity and affinity constant with the target are high.

03/12/2020

Can form a stable micellar structure.

Q&As

What is the dosage and usage of Il6?

The dosage and usage of Il6 will vary according to the disease, and generally require individualized regulation by the physician according to the disease situation.

What are the pharmacokinetic properties of Il6?

The pharmacokinetic characteristics of Il6 mainly include drug absorption, distribution, metabolism, excretion and other information.

Does Il6 have advantages in the treatment of multiple myeloma?

Recombinant Il6 protein has a unique therapeutic advantage in the treatment of multiple myeloma. It can promote the proliferation and differentiation of hematopoietic stem cells and inhibit the growth of tumor cells.

Does Il6 have specific therapeutic effects for certain diseases?

Il6 has specific therapeutic effects for certain diseases, such as rheumatoid arthritis, multiple myeloma and so on.

In which diseases is Il6 widely used?

This protein is widely used in the treatment of rheumatoid arthritis, pneumonia, multiple myeloma, lymphoma, malignant tumors and other diseases.

What is the effect of Il6 on immune cells?

The effects of Il6 on immune cells are mainly manifested as promoting cell proliferation and differentiation, regulating immune response, etc.